Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...

Cytokinetics' flagship program, aficamten, is a cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy (HCM), a condition characterized by thickening of the heart muscle.

BMS builds case ahead of FDA verdict The disappointing run of data with omecamtiv is in contrast to that of Bristol-Myers Squibb with its cardiac myosin inhibitor mavacamten. That drug is also ...

The US regulator has accepted Cytokinetics' marketing application for the cardiac myosin inhibitor, setting a target action date of 26th September 2025 to complete its review and, according to the ...

Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at https://www.cytokinetics.com. The webcast replay will be ...